# Liraglutide

Liraglutide has 419 registered human trials. It is marketed for 2 different uses.

**In short**

- 419 registered human trials exist for Liraglutide.
- Liraglutide is FDA-approved — FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications.
- What has actually been studied: uncontrolled type 1 diabetic patients, diabetes, diabetes mellitus, type 2.
- Last checked against ClinicalTrials.gov on 2026-07-30.

## What it is

Liraglutide is a GLP-1 analogue: 97% identical to the human hormone, with a fatty-acid chain attached so it binds to albumin in the blood and lasts long enough for once-daily injection. Novo Nordisk developed it, and the FDA approved it as Victoza in 2010 and as Saxenda for weight management in 2014.

## Where the claims come from

Liraglutide is not a grey-market compound and is not controversial. It is on this site as a comparison: it is the drug semaglutide and tirzepatide largely replaced, and its trial record shows what a fully developed peptide medicine looks like — hundreds of registered trials, published outcomes, and approvals tied to specific populations.

## What evidence exists outside the registry

Nearly four hundred registered interventional trials, plus an extensive published literature including cardiovascular outcome studies. Much of its recent registry presence is as the active comparator in trials of newer drugs, which is itself a sign of a mature evidence base.

**Sources for the above**

- [Victoza FDA label](https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22Victoza%22) — Approved for glycaemic control in type 2 diabetes, patients 10 and older, and cardiovascular risk reduction.
- [Saxenda FDA label](https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22Saxenda%22) — Approved for chronic weight management, with specific age and weight criteria.

## Approved for

FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications.

## Studied for

- Uncontrolled Type 1 Diabetic Patients
- Diabetes
- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type 2 Treated With Insulin
- Gestational Diabetes
- Healthy
- Severe Obesity
- Cardiovascular Function
- Liraglutide
- Childhood Obesity
- Echocardiography
- Speckle Tracking
- Type 1 Diabetes
- Acute Heart Failure
- Obesity, Childhood
- Neural Development
- Type 2 Diabetes
- Type 2 Diabetes (T2DM)
- Obesity
- Metabolism and Nutrition Disorder
- Diabetes Mellitus Type 2
- Metabolic Syndrome
- Cardiovascular Disease
- Diastolic Dysfunction
- Fatty Liver
- Osteoarthritis
- Overweight
- Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
- DIABETES Mellitus Type 2 Not Well Controlled
- Prediabetes
- Type2 Diabetes
- Diabetes Mellitus, Type 1
- Type 2 Diabetic Patients
- Type 2 Diabetes Mellitus
- Cushing's Disease
- Acromegaly
- Coronary Artery Disease
- Smoking Cessation
- Weight, Body
- Binge Eating Behaviour
- Growth Hormone Deficiency
- OSA
- Obesity, Adolescent
- Comparative Effectiveness of Glycemia-lowering Medications
- Mild Cognitive Impairment
- GLP-1；Metformin；Telomere-telomerase System；Par-4
- Diabetes Mellitus, Type II
- Cardiovascular Diseases
- Weight Loss
- Microbiome
- Acute Myocardial Infarction
- Congestive Heart Failure
- Osteoarthritis, Knee
- Heart Failure
- Gastroparesis
- Functional Dyspepsia
- Chronic Nausea and Vomiting Syndrome
- Kidney Failure, Chronic
- Prediabetic State
- Pulmonary Disease, Chronic Obstructive
- Treatment Adherence
- Acute ST-segment Elevation Myocardial Infarction
- Maturity-onset Diabetes of the Young
- Hyperglycemia
- Chronic Heart Failure
- T2DM (Type 2 Diabetes Mellitus)
- Sleep Apnea
- Sleep Disordered Breathing
- Autonomic Nervous System Diseases
- Sweat Gland Diseases
- Diabetic Neuropathy With Neurologic Complication
- Gestational Diabetes Mellitus
- Effects of Liraglutide Administration on Brain Activity
- Hunger
- Ischemic Stroke
- Transient Ischemic Attack
- HIV Infections
- Obstructive Sleep Apnoea
- Type 1 Diabetes Mellitus
- Polycystic Ovary Syndrome
- Infertility, Female
- PCOS
- Microvascular Angina
- Multiple Sclerosis
- Long COVID
- Long Covid19
- Obese
- Obesity, Morbid
- Acute Leukemia in Remission
- Impaired Glucose Tolerance Associated With Drugs
- Diabetes Mellitus
- Overweight and Obese Adults
- Morbid Obesity
- Peripheral Vascular Disorder Due to Diabetes Mellitus
- Opiate Substitution Treatment
- Opioid-Related Disorders
- Therapeutic Equivalency
- Bariatric Surgery Candidate
- Diabetes Mellitus, Adult-Onset
- Inflammation
- Diabetes Mellitus, Non-Insulin-Dependent
- Hypertensive Disease
- Nonalcoholic Steatohepatitis
- Diabetic Kidney Disease
- Pre Diabetes
- Obesity Android
- Psoriasis
- Non-Alcoholic Fatty Liver Disease
- Incretinomimetics
- Pancreas
- Mental Disorder
- Metabolic Disturbance
- Feasibility
- Overweight and Obesity
- Psoriatic Arthritis
- Impaired Glucose Tolerance
- Bipolar Disorder
- Metformin
- Obesity, Abdominal
- Abdominal Fat
- Metabolism Disorder, Glucose
- Metabolism Disorder, Lipid
- Systolic Hypertension
- Infertility
- Short Bowel Syndrome
- Pre-Diabetes
- Knee Osteoarthritis
- Status Post Sleeve Gastrectomy
- Type1 Diabetes Mellitus
- Autoimmune Diabetes
- Type 2 Diabetes Patients
- Hyperglycaemia (Diabetic)
- Bariatric Surgery
- Maturity Onset Diabetes of the Young
- Liraglutide Blood-brain Transfer
- Panhypopituitarism
- Craniopharyngioma
- Hypothalamic Obesity
- Healthy Human Male Subjects
- Atypical Endometrial Hyperplasia
- Fertility Issues
- Obesity, Visceral
- Fat Disorder
- Healthy Subjects
- Diabete Type 2
- Non-alcoholic Fatty Liver Disease
- Type II Diabetes in Subjects BMI 27 to 32
- Brain Death
- Hemodialysis
- Polycystic Ovary
- Diabesity
- Myocardial Infarction
- Disorder of Glucose Regulation
- Blood Pressure
- Diabetic Neuropathic Pain
- Hypogonadism
- Masked Hypertension
- Monoclonal Gammopathies
- Insulin Resistance
- Synovitis of Knee
- Bile Acid Malabsorption
- Diabetes Complications
- Osteoporosis
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Non-alcoholic Steatohepatitis (NASH)
- Sleep Apnea, Obstructive
- Binge-Eating Disorder
- Parkinson Disease
- Alzheimer's Disease
- HIV Infection
- Major Depressive Disorder
- Ischemic Cardiomyopathy
- Diabetes Mellitus Type II
- Pre-diabetes
- Older Adults
- Delirium, Postoperative
- Cardiac MRI
- Myocardial Perfusion
- Pouchitis
- Irritable Pouch Syndrome
- Glucocorticoid Induced Hyperglycemia
- Peripheral Arterial Disease
- Prader Willi Syndrome
- Microvascular Dysfunction
- PreDiabetes
- Type 2 Diabetes Treated With Insulin
- Adolescent Obesity
- Nonalcoholic Fatty Liver Disease
- Dementia
- End-stage Renal Disease
- Type II Diabetes Mellitus
- Atrial Fibrillation
- Polycystic Ovary Syndrome (PCOS)
- Ischaemic Heart Disease
- Coronary Heart Disease
- Chronic Stable Angina
- Fatty Liver, Nonalcoholic
- Alzheimers Disease
- Hypoglycemia
- Surgery
- Gastric Banding

## Marketed for

- Weight loss
- Blood sugar control

## What regulators have said

We searched FDA's list of bulk drug substances nominated for use in pharmacy compounding and did not find Liraglutide on it, in any category. There is no published FDA safety assessment to report — that is not the same as having been reviewed and cleared.


## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT01592279](https://clinicaltrials.gov/study/NCT01592279) | GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients | Uncontrolled Type 1 Diabetic Patients | Phase 4 | UNKNOWN | 124 |
| [NCT02100475](https://clinicaltrials.gov/study/NCT02100475) | A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 31 |
| [NCT02298192](https://clinicaltrials.gov/study/NCT02298192) | A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 420 |
| [NCT05767255](https://clinicaltrials.gov/study/NCT05767255) | Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue | Diabetes Mellitus, Type 2 Treated With Insulin | Phase 3 | UNKNOWN | 66 |
| [NCT04324229](https://clinicaltrials.gov/study/NCT04324229) | Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes | Gestational Diabetes | Not phased | ACTIVE_NOT_RECRUITING | 80 |
| [NCT00983021](https://clinicaltrials.gov/study/NCT00983021) | Safety and Tolerability of NN9068 in Healthy Male Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 24 |
| [NCT01511185](https://clinicaltrials.gov/study/NCT01511185) | Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 20 |
| [NCT07590219](https://clinicaltrials.gov/study/NCT07590219) | Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity | Severe Obesity, Cardiovascular Function | Phase 4 | ACTIVE_NOT_RECRUITING | 30 |
| [NCT01722266](https://clinicaltrials.gov/study/NCT01722266) | Liraglutide in the Treatment of Type 1 Diabetes Mellitus | Type 1 Diabetes | Phase 3 | COMPLETED | 72 |
| [NCT01800968](https://clinicaltrials.gov/study/NCT01800968) | Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) | Acute Heart Failure | Phase 2 | COMPLETED | 300 |
| [NCT03500484](https://clinicaltrials.gov/study/NCT03500484) | Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity. | Obesity, Childhood, Neural Development | Phase 1 | TERMINATED | 13 |
| [NCT02584582](https://clinicaltrials.gov/study/NCT02584582) | The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate | Type 1 Diabetes | Phase 3 | UNKNOWN | 10 |
| [NCT01319240](https://clinicaltrials.gov/study/NCT01319240) | Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 24 |
| [NCT01499108](https://clinicaltrials.gov/study/NCT01499108) | Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes | Type 2 Diabetes | Phase 4 | COMPLETED | 32 |
| [NCT07325435](https://clinicaltrials.gov/study/NCT07325435) | Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Type 2 Diabetes (T2DM) | Phase 4 | ACTIVE_NOT_RECRUITING | 60 |
| [NCT02351232](https://clinicaltrials.gov/study/NCT02351232) | The Lira Pump Trial | Type 1 Diabetes | Phase 3 | COMPLETED | 44 |
| [NCT01856790](https://clinicaltrials.gov/study/NCT01856790) | Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes | Type 1 Diabetes | Phase 1 | COMPLETED | 15 |
| [NCT00518882](https://clinicaltrials.gov/study/NCT00518882) | Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 467 |
| [NCT04839237](https://clinicaltrials.gov/study/NCT04839237) | The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients | Obesity | Phase 2 | WITHDRAWN | 0 |
| [NCT03191396](https://clinicaltrials.gov/study/NCT03191396) | Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 577 |
| [NCT00781937](https://clinicaltrials.gov/study/NCT00781937) | Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 422 |
| [NCT01761318](https://clinicaltrials.gov/study/NCT01761318) | Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients | Diabetes Mellitus Type 2, Metabolic Syndrome | Phase 4 | COMPLETED | 50 |
| [NCT02905864](https://clinicaltrials.gov/study/NCT02905864) | Liraglutide 3 mg for Knee Osteoarthritis | Osteoarthritis, Obesity | Phase 4 | COMPLETED | 150 |
| [NCT01388361](https://clinicaltrials.gov/study/NCT01388361) | Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 413 |
| [NCT01508806](https://clinicaltrials.gov/study/NCT01508806) | Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 30 |
| [NCT02674893](https://clinicaltrials.gov/study/NCT02674893) | Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes | Type 2 Diabetes, Overweight | Phase 4 | TERMINATED | 48 |
| [NCT05294536](https://clinicaltrials.gov/study/NCT05294536) | A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects | Type 2 Diabetes | Phase 1 | COMPLETED | 50 |
| [NCT00154401](https://clinicaltrials.gov/study/NCT00154401) | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 177 |
| [NCT01451905](https://clinicaltrials.gov/study/NCT01451905) | GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis | Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI | Not phased | UNKNOWN | 12 |
| [NCT01785043](https://clinicaltrials.gov/study/NCT01785043) | Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users | DIABETES Mellitus Type 2 Not Well Controlled | Phase 4 | COMPLETED | 13 |
| [NCT01664247](https://clinicaltrials.gov/study/NCT01664247) | The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 346 |
| [NCT01508923](https://clinicaltrials.gov/study/NCT01508923) | Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 17 |
| [NCT01779362](https://clinicaltrials.gov/study/NCT01779362) | RISE Adult Medication Study | Prediabetes, Type 2 Diabetes | Phase 3 | COMPLETED | 267 |
| [NCT02417103](https://clinicaltrials.gov/study/NCT02417103) | Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid | Obesity | Phase 3 | TERMINATED | 2 |
| [NCT01392573](https://clinicaltrials.gov/study/NCT01392573) | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 413 |
| [NCT01336023](https://clinicaltrials.gov/study/NCT01336023) | Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1663 |
| [NCT04190160](https://clinicaltrials.gov/study/NCT04190160) | Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira) | Type2 Diabetes | Not phased | COMPLETED | 35 |
| [NCT01744236](https://clinicaltrials.gov/study/NCT01744236) | SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies | Type 2 Diabetes | Phase 4 | COMPLETED | 70 |
| [NCT01536665](https://clinicaltrials.gov/study/NCT01536665) | The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes | Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | COMPLETED | 45 |
| [NCT05705388](https://clinicaltrials.gov/study/NCT05705388) | POSE2.0 With GLP-1 Agonist for Obesity Management | Obesity | Not phased | UNKNOWN | 50 |
| [NCT01593137](https://clinicaltrials.gov/study/NCT01593137) | A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes | Type 2 Diabetes | Phase 4 | WITHDRAWN | 0 |
| [NCT01836523](https://clinicaltrials.gov/study/NCT01836523) | The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes | Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | COMPLETED | 1398 |
| [NCT06925334](https://clinicaltrials.gov/study/NCT06925334) | A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus | Type 2 Diabetic Patients | Phase 4 | ENROLLING_BY_INVITATION | 170 |
| [NCT02787551](https://clinicaltrials.gov/study/NCT02787551) | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 514 |
| [NCT02501161](https://clinicaltrials.gov/study/NCT02501161) | A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1012 |
| [NCT03041792](https://clinicaltrials.gov/study/NCT03041792) | Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects | Obesity | Phase 1 | COMPLETED | 61 |
| [NCT01722240](https://clinicaltrials.gov/study/NCT01722240) | Liraglutide in Type 1 Diabetes | Type 1 Diabetes | Phase 3 | COMPLETED | 69 |
| [NCT02060383](https://clinicaltrials.gov/study/NCT02060383) | Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | Cushing's Disease, Acromegaly | Phase 4 | COMPLETED | 249 |
| [NCT03260881](https://clinicaltrials.gov/study/NCT03260881) | Liraglutide Effects on Epicardial Fat Inflammatory Genes | Type2 Diabetes, Coronary Artery Disease | Phase 4 | COMPLETED | 38 |
| [NCT03712098](https://clinicaltrials.gov/study/NCT03712098) | Daily Liraglutide for Nicotine Dependence | Smoking Cessation, Weight, Body | Phase 2 | COMPLETED | 40 |
| [NCT01620463](https://clinicaltrials.gov/study/NCT01620463) | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 32 |
| [NCT01739049](https://clinicaltrials.gov/study/NCT01739049) | Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese | Binge Eating Behaviour | Phase 4 | COMPLETED | 42 |
| [NCT03347890](https://clinicaltrials.gov/study/NCT03347890) | Reward Mechanisms in Obesity | Obesity | Phase 4 | COMPLETED | 70 |
| [NCT05681299](https://clinicaltrials.gov/study/NCT05681299) | Effects of GH and Lirglutide on AgRP | Healthy, Growth Hormone Deficiency | Phase 4 | RECRUITING | 40 |
| [NCT00318461](https://clinicaltrials.gov/study/NCT00318461) | To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1091 |
| [NCT06400615](https://clinicaltrials.gov/study/NCT06400615) | Study That Tests AD109 in Patients Taking GLP-1 Drugs | OSA | Phase 2 | COMPLETED | 40 |
| [NCT02721888](https://clinicaltrials.gov/study/NCT02721888) | Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism | Type 2 Diabetes | Phase 4 | TERMINATED | 127 |
| [NCT01518166](https://clinicaltrials.gov/study/NCT01518166) | Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH | Diabetes, Healthy | Phase 1 | COMPLETED | 70 |
| [NCT02963922](https://clinicaltrials.gov/study/NCT02963922) | Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 396 |
| [NCT02765399](https://clinicaltrials.gov/study/NCT02765399) | The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis | Type 2 Diabetes | Phase 4 | COMPLETED | 23 |
| [NCT06865365](https://clinicaltrials.gov/study/NCT06865365) | Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone | Obesity, Adolescent | Phase 4 | NOT_YET_RECRUITING | 72 |
| [NCT02043054](https://clinicaltrials.gov/study/NCT02043054) | Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) | Type 2 Diabetes Mellitus, Cardiovascular Disease | Phase 3 | COMPLETED | 90 |
| [NCT06818292](https://clinicaltrials.gov/study/NCT06818292) | Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists | Healthy | Not phased | COMPLETED | 10 |
| [NCT01794143](https://clinicaltrials.gov/study/NCT01794143) | A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications | Phase 3 | COMPLETED | 7850 |
| [NCT05579249](https://clinicaltrials.gov/study/NCT05579249) | A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America | Obesity | Phase 4 | COMPLETED | 500 |
| [NCT03856047](https://clinicaltrials.gov/study/NCT03856047) | Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Overweight, Obesity | Phase 2 | COMPLETED | 706 |
| [NCT01664676](https://clinicaltrials.gov/study/NCT01664676) | Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients | Type 2 Diabetes Mellitus | Phase 4 | COMPLETED | 11 |
| [NCT06449703](https://clinicaltrials.gov/study/NCT06449703) | A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects | Healthy | Phase 1 | UNKNOWN | 44 |
| [NCT05313529](https://clinicaltrials.gov/study/NCT05313529) | LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes | Type 2 Diabetes Mellitus, Mild Cognitive Impairment | Not phased | COMPLETED | 396 |
| [NCT02535299](https://clinicaltrials.gov/study/NCT02535299) | Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment | GLP-1；Metformin；Telomere-telomerase System；Par-4 | Phase 4 | UNKNOWN | 200 |
| [NCT02686177](https://clinicaltrials.gov/study/NCT02686177) | Effect of GLP-1 on Angiogenesis | Type 2 Diabetes | Phase 4 | COMPLETED | 50 |
| [NCT02527200](https://clinicaltrials.gov/study/NCT02527200) | Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 56 |
| [NCT02207348](https://clinicaltrials.gov/study/NCT02207348) | Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 24 |
| [NCT01654120](https://clinicaltrials.gov/study/NCT01654120) | Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics | Diabetes Mellitus, Type II | Phase 4 | COMPLETED | 37 |
| [NCT04057261](https://clinicaltrials.gov/study/NCT04057261) | Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease | Type 2 Diabetes, Cardiovascular Diseases | Phase 3 | WITHDRAWN | 0 |
| [NCT04046822](https://clinicaltrials.gov/study/NCT04046822) | Effect of Liraglutide on Microbiome in Obesity | Obesity, Weight Loss | Phase 4 | UNKNOWN | 70 |
| [NCT02001363](https://clinicaltrials.gov/study/NCT02001363) | Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury | Acute Myocardial Infarction | Not phased | UNKNOWN | 90 |
| [NCT04531176](https://clinicaltrials.gov/study/NCT04531176) | EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial | Type 2 Diabetes, Obesity | Phase 4 | TERMINATED | 74 |
| [NCT00395746](https://clinicaltrials.gov/study/NCT00395746) | Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 264 |
| [NCT02964247](https://clinicaltrials.gov/study/NCT02964247) | LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 303 |
| [NCT01425580](https://clinicaltrials.gov/study/NCT01425580) | Liraglutide and Heart Failure in Type 2 Diabetes | Congestive Heart Failure, Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 62 |
| [NCT02910570](https://clinicaltrials.gov/study/NCT02910570) | Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis | Osteoarthritis, Knee | Phase 4 | COMPLETED | 150 |
| [NCT02650596](https://clinicaltrials.gov/study/NCT02650596) | Effects of GLP-1 on Chronic Heart Failure | Heart Failure | Not phased | UNKNOWN | 68 |
| [NCT06500130](https://clinicaltrials.gov/study/NCT06500130) | Effects of Liraglutide on Body Surface Gastric Mapping | Gastroparesis, Functional Dyspepsia | Not phased | COMPLETED | 22 |
| [NCT02717858](https://clinicaltrials.gov/study/NCT02717858) | A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 52 |
| [NCT02072096](https://clinicaltrials.gov/study/NCT02072096) | A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 4 | TERMINATED | 192 |
| [NCT02284230](https://clinicaltrials.gov/study/NCT02284230) | The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure | Kidney Failure, Chronic, Prediabetic State | Phase 2 | WITHDRAWN | 0 |
| [NCT01617434](https://clinicaltrials.gov/study/NCT01617434) | The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 451 |
| [NCT03466021](https://clinicaltrials.gov/study/NCT03466021) | Effects of Liraglutide in Chronic Obstructive Pulmonary Disease | Pulmonary Disease, Chronic Obstructive | Phase 4 | COMPLETED | 40 |
| [NCT03374956](https://clinicaltrials.gov/study/NCT03374956) | Individualized Obesity Pharmacotherapy | Obesity | Phase 3 | COMPLETED | 193 |
| [NCT01272232](https://clinicaltrials.gov/study/NCT01272232) | Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 846 |
| [NCT01179048](https://clinicaltrials.gov/study/NCT01179048) | Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 9341 |
| [NCT06836284](https://clinicaltrials.gov/study/NCT06836284) | The Evira Study: Additional Support During Obesity Treatment | Childhood Obesity, Treatment Adherence | Not phased | RECRUITING | 40 |
| [NCT02507128](https://clinicaltrials.gov/study/NCT02507128) | Effects of Glucagon Like Peptide-1 on No-reflow | Acute ST-segment Elevation Myocardial Infarction | Not phased | UNKNOWN | 190 |
| [NCT03523273](https://clinicaltrials.gov/study/NCT03523273) | Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity | Obesity | Phase 2 | COMPLETED | 136 |
| [NCT01610934](https://clinicaltrials.gov/study/NCT01610934) | The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) | Maturity-onset Diabetes of the Young | Phase 3 | COMPLETED | 15 |
| [NCT05390307](https://clinicaltrials.gov/study/NCT05390307) | Obesity Treatment to Improve Diabetes | Type 1 Diabetes | Not phased | COMPLETED | 60 |
| [NCT02453711](https://clinicaltrials.gov/study/NCT02453711) | Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Metabolism and Nutrition Disorder, Obesity | Phase 2 | COMPLETED | 957 |
| [NCT01472640](https://clinicaltrials.gov/study/NCT01472640) | The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus | Hyperglycemia, Chronic Heart Failure | Not phased | COMPLETED | 240 |
| [NCT07244003](https://clinicaltrials.gov/study/NCT07244003) | Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | T2DM (Type 2 Diabetes Mellitus) | Phase 4 | RECRUITING | 430 |
| [NCT02931383](https://clinicaltrials.gov/study/NCT02931383) | Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance | Osteoarthritis, Obesity | Phase 4 | COMPLETED | 150 |
| [NCT01512108](https://clinicaltrials.gov/study/NCT01512108) | Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 363 |
| [NCT01832532](https://clinicaltrials.gov/study/NCT01832532) | A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks | Sleep Apnea, Sleep Disordered Breathing | Phase 2 | COMPLETED | 34 |
| [NCT03426085](https://clinicaltrials.gov/study/NCT03426085) | The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes | Autonomic Nervous System Diseases, Sweat Gland Diseases | Phase 2 | UNKNOWN | 44 |
| [NCT00993304](https://clinicaltrials.gov/study/NCT00993304) | A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 20 |
| [NCT01795248](https://clinicaltrials.gov/study/NCT01795248) | The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes | Gestational Diabetes Mellitus | Phase 4 | COMPLETED | 105 |
| [NCT06408532](https://clinicaltrials.gov/study/NCT06408532) | The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 4 | UNKNOWN | 256 |
| [NCT01562678](https://clinicaltrials.gov/study/NCT01562678) | Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI | Diabetes, Effects of Liraglutide Administration on Brain Activity | Phase 4 | COMPLETED | 28 |
| [NCT01917656](https://clinicaltrials.gov/study/NCT01917656) | Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 343 |
| [NCT01513525](https://clinicaltrials.gov/study/NCT01513525) | Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 21 |
| [NCT02490176](https://clinicaltrials.gov/study/NCT02490176) | Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters | Heart Failure | Not phased | UNKNOWN | 50 |
| [NCT00873223](https://clinicaltrials.gov/study/NCT00873223) | Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 33 |
| [NCT03948347](https://clinicaltrials.gov/study/NCT03948347) | Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus | Ischemic Stroke, Transient Ischemic Attack | Not phased | UNKNOWN | 1708 |
| [NCT03175120](https://clinicaltrials.gov/study/NCT03175120) | A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 453 |
| [NCT01954147](https://clinicaltrials.gov/study/NCT01954147) | Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus | Type 2 Diabetes | Phase 2 | UNKNOWN | 100 |
| [NCT01516255](https://clinicaltrials.gov/study/NCT01516255) | Effect of Liraglutide on Heart Frequency in Healthy Volunteers | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 64 |
| [NCT02205528](https://clinicaltrials.gov/study/NCT02205528) | A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Diabetes, Diabetes Mellitus Type 2 | Phase 2 | COMPLETED | 108 |
| [NCT05794581](https://clinicaltrials.gov/study/NCT05794581) | A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes | Type 1 Diabetes | Phase 1 | COMPLETED | 32 |
| [NCT01558271](https://clinicaltrials.gov/study/NCT01558271) | A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 492 |
| [NCT02617654](https://clinicaltrials.gov/study/NCT02617654) | Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes | Type 1 Diabetes | Phase 2 | COMPLETED | 18 |
| [NCT01208012](https://clinicaltrials.gov/study/NCT01208012) | Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 44 |
| [NCT06438146](https://clinicaltrials.gov/study/NCT06438146) | LIROH - Liraglutide for Obesity in HIV | Obesity, HIV Infections | Phase 4 | UNKNOWN | 40 |
| [NCT00700817](https://clinicaltrials.gov/study/NCT00700817) | The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 665 |
| [NCT02324842](https://clinicaltrials.gov/study/NCT02324842) | Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients | Type 2 Diabetes Mellitus | Not phased | COMPLETED | 45 |
| [NCT06976619](https://clinicaltrials.gov/study/NCT06976619) | The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes | Type 1 Diabetes, Type 2 Diabetes | Phase 2 | RECRUITING | 60 |
| [NCT00761540](https://clinicaltrials.gov/study/NCT00761540) | To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo | Diabetes, Healthy | Phase 1 | COMPLETED | 37 |
| [NCT01557166](https://clinicaltrials.gov/study/NCT01557166) | Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 359 |
| [NCT02344186](https://clinicaltrials.gov/study/NCT02344186) | Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes | Type 2 Diabetes | Phase 4 | UNKNOWN | 12 |
| [NCT02773368](https://clinicaltrials.gov/study/NCT02773368) | A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 420 |
| [NCT03862716](https://clinicaltrials.gov/study/NCT03862716) | Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 159 |
| [NCT02518945](https://clinicaltrials.gov/study/NCT02518945) | Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes | Type 1 Diabetes Mellitus | Phase 3 | COMPLETED | 26 |
| [NCT05952882](https://clinicaltrials.gov/study/NCT05952882) | Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility | Polycystic Ovary Syndrome, Obesity | Phase 3 | UNKNOWN | 188 |
| [NCT03795701](https://clinicaltrials.gov/study/NCT03795701) | To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity | Obesity | Not phased | COMPLETED | 73 |
| [NCT05268627](https://clinicaltrials.gov/study/NCT05268627) | Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss | Obesity | Not phased | UNKNOWN | 38 |
| [NCT03642600](https://clinicaltrials.gov/study/NCT03642600) | The Gut Microbiome in Women With Polycystic Ovary Syndrome | PCOS, Obesity | Phase 4 | COMPLETED | 21 |
| [NCT02696148](https://clinicaltrials.gov/study/NCT02696148) | A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 24 |
| [NCT02647944](https://clinicaltrials.gov/study/NCT02647944) | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | Obesity | Phase 2 | COMPLETED | 40 |
| [NCT03449654](https://clinicaltrials.gov/study/NCT03449654) | Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 102 |
| [NCT01782261](https://clinicaltrials.gov/study/NCT01782261) | Incretin Effect on the Immunological Phenotype | Type 1 Diabetes | Phase 2 | COMPLETED | 15 |
| [NCT02602600](https://clinicaltrials.gov/study/NCT02602600) | Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis | Microvascular Angina | Phase 4 | COMPLETED | 33 |
| [NCT06171152](https://clinicaltrials.gov/study/NCT06171152) | Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues | Multiple Sclerosis, Long COVID | Phase 1 | SUSPENDED | 30 |
| [NCT02870231](https://clinicaltrials.gov/study/NCT02870231) | Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 187 |
| [NCT01845259](https://clinicaltrials.gov/study/NCT01845259) | Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? | Impaired Glucose Tolerance Associated With Drugs | Phase 2 | UNKNOWN | 103 |
| [NCT01517568](https://clinicaltrials.gov/study/NCT01517568) | Metabolism and Excretion of Liraglutide in Healthy Male Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 7 |
| [NCT00993720](https://clinicaltrials.gov/study/NCT00993720) | Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes | Diabetes Mellitus | Phase 3 | COMPLETED | 30 |
| [NCT00856986](https://clinicaltrials.gov/study/NCT00856986) | The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 987 |
| [NCT01620489](https://clinicaltrials.gov/study/NCT01620489) | Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 279 |
| [NCT07301437](https://clinicaltrials.gov/study/NCT07301437) | RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. | Overweight and Obese Adults | Phase 4 | NOT_YET_RECRUITING | 120 |
| [NCT01966978](https://clinicaltrials.gov/study/NCT01966978) | The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study | Diabetes Mellitus, Type 2, Diabetes | Phase 4 | COMPLETED | 157 |
| [NCT05285397](https://clinicaltrials.gov/study/NCT05285397) | Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries. | Morbid Obesity | Not phased | UNKNOWN | 60 |
| [NCT05360537](https://clinicaltrials.gov/study/NCT05360537) | Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 100 |
| [NCT02516657](https://clinicaltrials.gov/study/NCT02516657) | Liraglutide in Adolescents With Type 1 Diabetes | Type 1 Diabetes | Phase 3 | COMPLETED | 5 |
| [NCT03034941](https://clinicaltrials.gov/study/NCT03034941) | Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients | Obesity, PCOS | Phase 4 | COMPLETED | 35 |
| [NCT02908087](https://clinicaltrials.gov/study/NCT02908087) | Incretin-based Therapy in Early Diagnosed Type 1 Diabetes | Type 1 Diabetes | Phase 2 | COMPLETED | 13 |
| [NCT02718950](https://clinicaltrials.gov/study/NCT02718950) | Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans | Obesity, Type 2 Diabetes Mellitus | Phase 3 | UNKNOWN | 20 |
| [NCT01270789](https://clinicaltrials.gov/study/NCT01270789) | LIraglutide and Beta-cell RepAir (LIBRA) Study | Type 2 Diabetes | Phase 3 | COMPLETED | 63 |
| [NCT01620476](https://clinicaltrials.gov/study/NCT01620476) | Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 24 |
| [NCT04146155](https://clinicaltrials.gov/study/NCT04146155) | Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease | Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus | Phase 4 | UNKNOWN | 200 |
| [NCT04199728](https://clinicaltrials.gov/study/NCT04199728) | Use of a GLP-1R Agonist to Treat Opioid Use Disorder | Opiate Substitution Treatment, Opioid-Related Disorders | Phase 2 | COMPLETED | 27 |
| [NCT01596504](https://clinicaltrials.gov/study/NCT01596504) | Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 142 |
| [NCT02057172](https://clinicaltrials.gov/study/NCT02057172) | Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 254 |
| [NCT05225974](https://clinicaltrials.gov/study/NCT05225974) | A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects | Therapeutic Equivalency | Phase 1 | COMPLETED | 32 |
| [NCT06201819](https://clinicaltrials.gov/study/NCT06201819) | Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery | Weight Loss, Bariatric Surgery Candidate | Phase 4 | COMPLETED | 37 |
| [NCT02650206](https://clinicaltrials.gov/study/NCT02650206) | Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood | Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II | Phase 1 | COMPLETED | 56 |
| [NCT01515553](https://clinicaltrials.gov/study/NCT01515553) | Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 22 |
| [NCT01879917](https://clinicaltrials.gov/study/NCT01879917) | Liraglutide in Newly Onset Type 1 Diabetes. | Diabetes Mellitus, Type 1 | Phase 3 | COMPLETED | 65 |
| [NCT02299388](https://clinicaltrials.gov/study/NCT02299388) | To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study | Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease | Phase 4 | COMPLETED | 11 |
| [NCT02889510](https://clinicaltrials.gov/study/NCT02889510) | Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes | Phase 3 | COMPLETED | 76 |
| [NCT01272219](https://clinicaltrials.gov/study/NCT01272219) | Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 3731 |
| [NCT04311411](https://clinicaltrials.gov/study/NCT04311411) | A Study of Tirzepatide in Overweight and Very Overweight Participants | Obesity, Overweight | Phase 1 | COMPLETED | 114 |
| [NCT04122716](https://clinicaltrials.gov/study/NCT04122716) | Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet | Obesity | Phase 4 | UNKNOWN | 215 |
| [NCT01507272](https://clinicaltrials.gov/study/NCT01507272) | Safety and Tolerability of Liraglutide in Healthy Male Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 34 |
| [NCT03172494](https://clinicaltrials.gov/study/NCT03172494) | A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 720 |
| [NCT00943501](https://clinicaltrials.gov/study/NCT00943501) | Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 21 |
| [NCT03353948](https://clinicaltrials.gov/study/NCT03353948) | The Effect of a Liraglutide on IVF in Obese PCOS | Polycystic Ovary Syndrome, Obesity | Phase 4 | COMPLETED | 30 |
| [NCT01128894](https://clinicaltrials.gov/study/NCT01128894) | A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 841 |
| [NCT04605861](https://clinicaltrials.gov/study/NCT04605861) | The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients | Obese, Overweight | Phase 3 | COMPLETED | 414 |
| [NCT01507285](https://clinicaltrials.gov/study/NCT01507285) | Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT02231658](https://clinicaltrials.gov/study/NCT02231658) | Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion | Diabetes Mellitus | Phase 1 | TERMINATED | 109 |
| [NCT02909933](https://clinicaltrials.gov/study/NCT02909933) | Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity | Polycystic Ovary Syndrome, Obesity | Phase 4 | COMPLETED | 30 |
| [NCT03036800](https://clinicaltrials.gov/study/NCT03036800) | Saxenda in Obesity Services (STRIVE Study) | Obesity, Weight Loss | Phase 4 | COMPLETED | 392 |
| [NCT04903509](https://clinicaltrials.gov/study/NCT04903509) | A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide | Healthy | Phase 1 | COMPLETED | 95 |
| [NCT04525300](https://clinicaltrials.gov/study/NCT04525300) | Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities | Obesity | Phase 3 | UNKNOWN | 300 |
| [NCT01363609](https://clinicaltrials.gov/study/NCT01363609) | Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes | Obesity, Type 2 Diabetes | Not phased | COMPLETED | 50 |
| [NCT03883412](https://clinicaltrials.gov/study/NCT03883412) | Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | Type2 Diabetes | Phase 4 | UNKNOWN | 60 |
| [NCT02292290](https://clinicaltrials.gov/study/NCT02292290) | Trial for People With Established Type 2 Diabetes During Ramadan | Type 2 Diabetes | Phase 4 | COMPLETED | 99 |
| [NCT01237119](https://clinicaltrials.gov/study/NCT01237119) | Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis | Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 52 |
| [NCT02082496](https://clinicaltrials.gov/study/NCT02082496) | GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations | Obesity | Phase 2 | COMPLETED | 50 |
| [NCT02545738](https://clinicaltrials.gov/study/NCT02545738) | Antiproteinuric Effects of Liraglutide Treatment | Diabetic Kidney Disease | Phase 4 | COMPLETED | 32 |
| [NCT01509755](https://clinicaltrials.gov/study/NCT01509755) | Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 196 |
| [NCT03480022](https://clinicaltrials.gov/study/NCT03480022) | Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Pre Diabetes, Polycystic Ovary Syndrome | Phase 3 | COMPLETED | 88 |
| [NCT01460069](https://clinicaltrials.gov/study/NCT01460069) | The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis | Psoriasis | Not phased | COMPLETED | 20 |
| [NCT01787916](https://clinicaltrials.gov/study/NCT01787916) | 52 Week Trial of Liraglutide in Type 1 Diabetes | Type 1 Diabetes | Phase 4 | COMPLETED | 15 |
| [NCT02073929](https://clinicaltrials.gov/study/NCT02073929) | LIPT - Liraglutide in Polycystic Ovary Syndrome | Polycystic Ovary Syndrome, Cardiovascular Disease | Phase 4 | COMPLETED | 72 |
| [NCT03068065](https://clinicaltrials.gov/study/NCT03068065) | Antidiabetic Effects on Intrahepatic Fat | Non-Alcoholic Fatty Liver Disease, Type2 Diabetes | Phase 4 | COMPLETED | 87 |
| [NCT02244164](https://clinicaltrials.gov/study/NCT02244164) | Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. | Type 2 Diabetes, Incretinomimetics | Not phased | TERMINATED | 5 |
| [NCT01870297](https://clinicaltrials.gov/study/NCT01870297) | A Study of LY3025876 in Participants With Diabetes | Type 2 Diabetes Mellitus | Phase 1 | COMPLETED | 72 |
| [NCT01755416](https://clinicaltrials.gov/study/NCT01755416) | Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting | Type 1 Diabetes | Phase 2 | COMPLETED | 18 |
| [NCT04781998](https://clinicaltrials.gov/study/NCT04781998) | Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry? | Mental Disorder, Metabolic Disturbance | Phase 4 | COMPLETED | 24 |
| [NCT01740921](https://clinicaltrials.gov/study/NCT01740921) | GLP-1 and Microvascular Function in Type 2 Diabetes | Type 2 Diabetes | Not phased | COMPLETED | 39 |
| [NCT02472717](https://clinicaltrials.gov/study/NCT02472717) | Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study | Psoriatic Arthritis, Psoriasis | Phase 2 | WITHDRAWN | 0 |
| [NCT01638260](https://clinicaltrials.gov/study/NCT01638260) | GLP-1 and Non-exercise Activity Thermogenesis in RHZ | Type 2 Diabetes Mellitus | Phase 4 | TERMINATED | 22 |
| [NCT01117350](https://clinicaltrials.gov/study/NCT01117350) | Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 978 |
| [NCT03158805](https://clinicaltrials.gov/study/NCT03158805) | Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) | Bipolar Disorder, Obesity | Phase 2 | COMPLETED | 60 |
| [NCT05779644](https://clinicaltrials.gov/study/NCT05779644) | Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus | Metformin, Obesity, Abdominal | Not phased | UNKNOWN | 300 |
| [NCT01755572](https://clinicaltrials.gov/study/NCT01755572) | Blood Pressure Outcomes With Liraglutide Therapy | Type 2 Diabetes, Systolic Hypertension | Phase 4 | COMPLETED | 22 |
| [NCT01517555](https://clinicaltrials.gov/study/NCT01517555) | Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 18 |
| [NCT02638805](https://clinicaltrials.gov/study/NCT02638805) | Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 136 |
| [NCT02832999](https://clinicaltrials.gov/study/NCT02832999) | Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 4 | COMPLETED | 14 |
| [NCT06742710](https://clinicaltrials.gov/study/NCT06742710) | Liraglutide Treatment in Obese Infertile PCOS Women | PCOS, Obesity | Phase 4 | RECRUITING | 890 |
| [NCT03371862](https://clinicaltrials.gov/study/NCT03371862) | Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) | Short Bowel Syndrome | Phase 2 | WITHDRAWN | 0 |
| [NCT01206101](https://clinicaltrials.gov/study/NCT01206101) | Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation | Diabetes, Diabetes Mellitus, Type 1 | Phase 2 | TERMINATED | 3 |
| [NCT02488057](https://clinicaltrials.gov/study/NCT02488057) | Improving Beta Cell Function in Mexican American Women With Prediabetes | Pre-Diabetes | Phase 4 | COMPLETED | 360 |
| [NCT01595789](https://clinicaltrials.gov/study/NCT01595789) | The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes | Coronary Artery Disease, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 41 |
| [NCT02973321](https://clinicaltrials.gov/study/NCT02973321) | A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 296 |
| [NCT02138045](https://clinicaltrials.gov/study/NCT02138045) | Treatment of Diabetic Neuropathy With Liraglutide | Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus | Not phased | COMPLETED | 39 |
| [NCT05419856](https://clinicaltrials.gov/study/NCT05419856) | Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee | Knee Osteoarthritis | Phase 1 | COMPLETED | 34 |
| [NCT03341429](https://clinicaltrials.gov/study/NCT03341429) | Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response | Obesity | Phase 4 | COMPLETED | 70 |
| [NCT05467514](https://clinicaltrials.gov/study/NCT05467514) | Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | Phase 3 | COMPLETED | 35 |
| [NCT01511692](https://clinicaltrials.gov/study/NCT01511692) | Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 43 |
| [NCT00154414](https://clinicaltrials.gov/study/NCT00154414) | Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 226 |
| [NCT01455441](https://clinicaltrials.gov/study/NCT01455441) | The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes | Type 2 Diabetes | Phase 4 | COMPLETED | 40 |
| [NCT02092896](https://clinicaltrials.gov/study/NCT02092896) | Liraglutide as add-on to Insulin in Type 1 Diabetes | Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | COMPLETED | 40 |
| [NCT02008682](https://clinicaltrials.gov/study/NCT02008682) | The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 368 |
| [NCT04883346](https://clinicaltrials.gov/study/NCT04883346) | Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Obesity, Status Post Sleeve Gastrectomy | Phase 2 | COMPLETED | 34 |
| [NCT03292185](https://clinicaltrials.gov/study/NCT03292185) | A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT01514487](https://clinicaltrials.gov/study/NCT01514487) | Comparison of Three Liraglutide Formulations in Healthy Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 24 |
| [NCT01029886](https://clinicaltrials.gov/study/NCT01029886) | Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 912 |
| [NCT01952145](https://clinicaltrials.gov/study/NCT01952145) | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 557 |
| [NCT03011021](https://clinicaltrials.gov/study/NCT03011021) | Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes | Type1 Diabetes Mellitus, Autoimmune Diabetes | Phase 2 | UNKNOWN | 40 |
| [NCT03087032](https://clinicaltrials.gov/study/NCT03087032) | Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) | Type 2 Diabetes Patients, Overweight and Obesity | Phase 4 | RECRUITING | 164 |
| [NCT04643301](https://clinicaltrials.gov/study/NCT04643301) | Liraglutide for Low-responders After Bariatric Surgery | Obesity, Obesity, Morbid | Not phased | WITHDRAWN | 0 |
| [NCT03010683](https://clinicaltrials.gov/study/NCT03010683) | Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus | Type 2 Diabetes Mellitus, Coronary Artery Disease | Not phased | COMPLETED | 60 |
| [NCT01518101](https://clinicaltrials.gov/study/NCT01518101) | Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications | Type 2 Diabetes | Phase 4 | COMPLETED | 62 |
| [NCT03115424](https://clinicaltrials.gov/study/NCT03115424) | Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | Obesity | Phase 3 | COMPLETED | 46 |
| [NCT06439056](https://clinicaltrials.gov/study/NCT06439056) | Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D | Type 2 Diabetes | Phase 1 | COMPLETED | 12 |
| [NCT07374445](https://clinicaltrials.gov/study/NCT07374445) | Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery | Obesity, Weight Loss | Phase 4 | COMPLETED | 100 |
| [NCT04325581](https://clinicaltrials.gov/study/NCT04325581) | Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients | Weight Loss | Phase 3 | COMPLETED | 16 |
| [NCT02928679](https://clinicaltrials.gov/study/NCT02928679) | Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance | Osteoarthritis, Obesity | Phase 4 | COMPLETED | 150 |
| [NCT01296412](https://clinicaltrials.gov/study/NCT01296412) | Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 653 |
| [NCT00696657](https://clinicaltrials.gov/study/NCT00696657) | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 415 |
| [NCT02730377](https://clinicaltrials.gov/study/NCT02730377) | Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 1991 |
| [NCT07029009](https://clinicaltrials.gov/study/NCT07029009) | Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) | Maturity Onset Diabetes of the Young | Phase 2 | RECRUITING | 50 |
| [NCT02104037](https://clinicaltrials.gov/study/NCT02104037) | Liraglutide in Spinal Fluid | Liraglutide Blood-brain Transfer | Not phased | COMPLETED | 8 |
| [NCT02918279](https://clinicaltrials.gov/study/NCT02918279) | Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 251 |
| [NCT06217848](https://clinicaltrials.gov/study/NCT06217848) | The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study | Panhypopituitarism, Craniopharyngioma | Phase 1 | UNKNOWN | 50 |
| [NCT02783196](https://clinicaltrials.gov/study/NCT02783196) | Effect of Liraglutide on Clock Genes | Type 2 Diabetes | Not phased | UNKNOWN | 14 |
| [NCT06533527](https://clinicaltrials.gov/study/NCT06533527) | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Diabetes Mellitus, Type 2, Obesity | Phase 4 | COMPLETED | 69 |
| [NCT01695109](https://clinicaltrials.gov/study/NCT01695109) | The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers | Healthy Human Male Subjects | Phase 4 | COMPLETED | 16 |
| [NCT02611232](https://clinicaltrials.gov/study/NCT02611232) | Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults | Type 1 Diabetes | Phase 2 | UNKNOWN | 42 |
| [NCT04683237](https://clinicaltrials.gov/study/NCT04683237) | Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia | Atypical Endometrial Hyperplasia, Obese | Phase 3 | WITHDRAWN | 0 |
| [NCT01982630](https://clinicaltrials.gov/study/NCT01982630) | Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003) | Diabetes Mellitus | Phase 1 | COMPLETED | 87 |
| [NCT01628445](https://clinicaltrials.gov/study/NCT01628445) | Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin | Type 2 Diabetes | Phase 3 | TERMINATED | 52 |
| [NCT02109315](https://clinicaltrials.gov/study/NCT02109315) | Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes. | Type 1 Diabetes Mellitus | Phase 1 | WITHDRAWN | 0 |
| [NCT02963935](https://clinicaltrials.gov/study/NCT02963935) | Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 282 |
| [NCT02777073](https://clinicaltrials.gov/study/NCT02777073) | Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes | Type 1 Diabetes | Not phased | COMPLETED | 43 |
| [NCT04775082](https://clinicaltrials.gov/study/NCT04775082) | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 78 |
| [NCT02863419](https://clinicaltrials.gov/study/NCT02863419) | Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 711 |
| [NCT01907854](https://clinicaltrials.gov/study/NCT01907854) | Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin | Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 407 |
| [NCT00393718](https://clinicaltrials.gov/study/NCT00393718) | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 400 |
| [NCT04373967](https://clinicaltrials.gov/study/NCT04373967) | Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes | Type 2 Diabetes | Phase 3 | UNKNOWN | 424 |
| [NCT02911948](https://clinicaltrials.gov/study/NCT02911948) | A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 210 |
| [NCT01658501](https://clinicaltrials.gov/study/NCT01658501) | Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 593 |
| [NCT01515579](https://clinicaltrials.gov/study/NCT01515579) | Comparison of Two Liraglutide Formulations in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 22 |
| [NCT03038620](https://clinicaltrials.gov/study/NCT03038620) | Impact of Liraglutide 3.0 on Body Fat Distribution | Obesity, Visceral, Cardiovascular Diseases | Phase 4 | COMPLETED | 235 |
| [NCT03707171](https://clinicaltrials.gov/study/NCT03707171) | Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 30 |
| [NCT04487743](https://clinicaltrials.gov/study/NCT04487743) | Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities | Obesity | Phase 3 | UNKNOWN | 300 |
| [NCT01687582](https://clinicaltrials.gov/study/NCT01687582) | Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients | Type 2 Diabetes, Psoriasis | Not phased | COMPLETED | 10 |
| [NCT01934816](https://clinicaltrials.gov/study/NCT01934816) | Incretin and KATP Channels | Healthy Subjects | Not phased | TERMINATED | 2 |
| [NCT05268237](https://clinicaltrials.gov/study/NCT05268237) | Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus | Diabete Type 2 | Phase 2 | RECRUITING | 15 |
| [NCT06501326](https://clinicaltrials.gov/study/NCT06501326) | Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease | Non-alcoholic Fatty Liver Disease, Obesity | Phase 4 | UNKNOWN | 102 |
| [NCT02041234](https://clinicaltrials.gov/study/NCT02041234) | Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment | Type II Diabetes in Subjects BMI 27 to 32 | Phase 4 | COMPLETED | 40 |
| [NCT03672812](https://clinicaltrials.gov/study/NCT03672812) | The Use of Liraglutide in Brain Death | Brain Death | Phase 3 | COMPLETED | 50 |
| [NCT04529278](https://clinicaltrials.gov/study/NCT04529278) | Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients | Diabetes Mellitus, Type 2, Hemodialysis | Phase 2 | UNKNOWN | 18 |
| [NCT02960659](https://clinicaltrials.gov/study/NCT02960659) | Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 24 |
| [NCT01725126](https://clinicaltrials.gov/study/NCT01725126) | To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes | Obesity | Phase 2 | COMPLETED | 53 |
| [NCT04535960](https://clinicaltrials.gov/study/NCT04535960) | Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial | Type 2 Diabetes Mellitus | Phase 2 | UNKNOWN | 36 |
| [NCT05965908](https://clinicaltrials.gov/study/NCT05965908) | Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome | Polycystic Ovary | Phase 3 | COMPLETED | 150 |
| [NCT03486392](https://clinicaltrials.gov/study/NCT03486392) | A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants | Obesity | Phase 2 | COMPLETED | 474 |
| [NCT02055014](https://clinicaltrials.gov/study/NCT02055014) | Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) | Type 2 Diabetes, Obesity | Phase 4 | UNKNOWN | 72 |
| [NCT01508858](https://clinicaltrials.gov/study/NCT01508858) | Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 21 |
| [NCT01722227](https://clinicaltrials.gov/study/NCT01722227) | Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes | Type 1 Diabetes | Phase 3 | WITHDRAWN | 0 |
| [NCT01615978](https://clinicaltrials.gov/study/NCT01615978) | Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 15 |
| [NCT02577848](https://clinicaltrials.gov/study/NCT02577848) | GLP-1 on Non-ST-Segment Elevation Myocardial Infarction | Myocardial Infarction | Not phased | UNKNOWN | 90 |
| [NCT04008290](https://clinicaltrials.gov/study/NCT04008290) | The Effect of Liraglutide on the GIT | Obesity | Phase 4 | UNKNOWN | 15 |
| [NCT01234649](https://clinicaltrials.gov/study/NCT01234649) | Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 153 |
| [NCT01790308](https://clinicaltrials.gov/study/NCT01790308) | Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function | Diabetes Mellitus, Type 2 | Phase 4 | UNKNOWN | 100 |
| [NCT02616003](https://clinicaltrials.gov/study/NCT02616003) | Preoperative Condition in Giant Obese Patients | Morbid Obesity, Bariatric Surgery Candidate | Phase 4 | COMPLETED | 50 |
| [NCT04575194](https://clinicaltrials.gov/study/NCT04575194) | Study of the Cardiometabolic Effects of Obesity Pharmacotherapy | Obesity, Blood Pressure | Phase 4 | UNKNOWN | 40 |
| [NCT02198209](https://clinicaltrials.gov/study/NCT02198209) | Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation | Type 2 Diabetes | Phase 4 | WITHDRAWN | 0 |
| [NCT04137328](https://clinicaltrials.gov/study/NCT04137328) | Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide | Diabetic Neuropathic Pain | Not phased | UNKNOWN | 60 |
| [NCT03619330](https://clinicaltrials.gov/study/NCT03619330) | Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. | Hypogonadism, Obesity | Phase 4 | COMPLETED | 30 |
| [NCT04074161](https://clinicaltrials.gov/study/NCT04074161) | Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Overweight, Obesity | Phase 3 | COMPLETED | 338 |
| [NCT06559722](https://clinicaltrials.gov/study/NCT06559722) | A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | NOT_YET_RECRUITING | 510 |
| [NCT01624259](https://clinicaltrials.gov/study/NCT01624259) | A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes | Type 2 Diabetes | Phase 3 | COMPLETED | 599 |
| [NCT03632759](https://clinicaltrials.gov/study/NCT03632759) | Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D | Type 1 Diabetes Mellitus | Phase 1 | COMPLETED | 16 |
| [NCT02503943](https://clinicaltrials.gov/study/NCT02503943) | Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes | Type 2 Diabetes, Overweight | Phase 4 | UNKNOWN | 90 |
| [NCT02920190](https://clinicaltrials.gov/study/NCT02920190) | Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat | Monoclonal Gammopathies, Overweight | Phase 4 | WITHDRAWN | 0 |
| [NCT02403284](https://clinicaltrials.gov/study/NCT02403284) | The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans | Insulin Resistance | Phase 4 | COMPLETED | 97 |
| [NCT01919489](https://clinicaltrials.gov/study/NCT01919489) | Liraglutide Hospital Discharge Trial | Type 2 Diabetes | Phase 4 | COMPLETED | 273 |
| [NCT07225829](https://clinicaltrials.gov/study/NCT07225829) | A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | Knee Osteoarthritis, Synovitis of Knee | Phase 2 | ACTIVE_NOT_RECRUITING | 129 |
| [NCT03757130](https://clinicaltrials.gov/study/NCT03757130) | Multiple Ascending Dose Study of AMG 598 in Adults With Obesity | Obesity | Phase 1 | COMPLETED | 50 |
| [NCT01509742](https://clinicaltrials.gov/study/NCT01509742) | Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 19 |
| [NCT03955575](https://clinicaltrials.gov/study/NCT03955575) | Treatment of Bile Acid Malabsorption With Liraglutide | Bile Acid Malabsorption | Phase 4 | COMPLETED | 52 |
| [NCT01911468](https://clinicaltrials.gov/study/NCT01911468) | Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin | PCOS, Obesity | Phase 4 | COMPLETED | 36 |
| [NCT02187250](https://clinicaltrials.gov/study/NCT02187250) | PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome | PCOS, Obesity | Phase 4 | COMPLETED | 45 |
| [NCT01515592](https://clinicaltrials.gov/study/NCT01515592) | Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT03048578](https://clinicaltrials.gov/study/NCT03048578) | Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery | Obesity | Phase 4 | COMPLETED | 132 |
| [NCT03235050](https://clinicaltrials.gov/study/NCT03235050) | A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 834 |
| [NCT01507389](https://clinicaltrials.gov/study/NCT01507389) | Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT05360147](https://clinicaltrials.gov/study/NCT05360147) | Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 30 |
| [NCT01550653](https://clinicaltrials.gov/study/NCT01550653) | Liraglutide Effects on Memory in Healthy Subjects | Healthy | Phase 1 | COMPLETED | 40 |
| [NCT02443155](https://clinicaltrials.gov/study/NCT02443155) | A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function | Diabetes, Diabetes Mellitus, Type 1 | Phase 2 | COMPLETED | 308 |
| [NCT03555994](https://clinicaltrials.gov/study/NCT03555994) | A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 51 |
| [NCT05444569](https://clinicaltrials.gov/study/NCT05444569) | A Study of LY3537021 in Healthy Participants | Healthy | Phase 1 | COMPLETED | 47 |
| [NCT01916174](https://clinicaltrials.gov/study/NCT01916174) | A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 50 |
| [NCT03534310](https://clinicaltrials.gov/study/NCT03534310) | Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg | Obesity | Not phased | COMPLETED | 75 |
| [NCT03018028](https://clinicaltrials.gov/study/NCT03018028) | Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 243 |
| [NCT00620282](https://clinicaltrials.gov/study/NCT00620282) | The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 49 |
| [NCT03520062](https://clinicaltrials.gov/study/NCT03520062) | The Effect of Liraglutide on Pancreatic Hormones and Its Size | Obesity | Not phased | COMPLETED | 14 |
| [NCT02473809](https://clinicaltrials.gov/study/NCT02473809) | The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function | Diabetes Complications, Osteoporosis | Phase 4 | COMPLETED | 60 |
| [NCT01392898](https://clinicaltrials.gov/study/NCT01392898) | Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | Not phased | UNKNOWN | 50 |
| [NCT02654665](https://clinicaltrials.gov/study/NCT02654665) | Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults | Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss | Phase 3 | UNKNOWN | 36 |
| [NCT03671733](https://clinicaltrials.gov/study/NCT03671733) | Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | Obesity | Phase 3 | UNKNOWN | 150 |
| [NCT03011008](https://clinicaltrials.gov/study/NCT03011008) | Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus | Type 1 Diabetes Mellitus, Autoimmune Diabetes | Phase 4 | UNKNOWN | 20 |
| [NCT00294723](https://clinicaltrials.gov/study/NCT00294723) | To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | TERMINATED | 746 |
| [NCT01508897](https://clinicaltrials.gov/study/NCT01508897) | Comparison of Two Liraglutide Formulations in Healthy Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 22 |
| [NCT01232946](https://clinicaltrials.gov/study/NCT01232946) | Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake | Type 2 Diabetes | Not phased | COMPLETED | 30 |
| [NCT04575844](https://clinicaltrials.gov/study/NCT04575844) | Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome | Metabolic Syndrome | Phase 4 | RECRUITING | 80 |
| [NCT01373450](https://clinicaltrials.gov/study/NCT01373450) | Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222) | Type 2 Diabetes Mellitus | Phase 1 | COMPLETED | 12 |
| [NCT04186494](https://clinicaltrials.gov/study/NCT04186494) | Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea | Sleep Apnea, Obstructive | Not phased | COMPLETED | 30 |
| [NCT03279731](https://clinicaltrials.gov/study/NCT03279731) | Binge Eating Liraglutide Intervention | Binge-Eating Disorder | Phase 3 | TERMINATED | 36 |
| [NCT02953665](https://clinicaltrials.gov/study/NCT02953665) | Safety and Efficacy of Liraglutide in Parkinson's Disease | Parkinson Disease | Phase 2 | COMPLETED | 63 |
| [NCT02898506](https://clinicaltrials.gov/study/NCT02898506) | Incretin-based Therapy in Late Preclinical Type 1 Diabetes | Type 1 Diabetes | Phase 2 | COMPLETED | 13 |
| [NCT00333151](https://clinicaltrials.gov/study/NCT00333151) | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 576 |
| [NCT01175473](https://clinicaltrials.gov/study/NCT01175473) | Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 148 |
| [NCT01973231](https://clinicaltrials.gov/study/NCT01973231) | Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 404 |
| [NCT01843075](https://clinicaltrials.gov/study/NCT01843075) | Evaluating Liraglutide in Alzheimer's Disease | Alzheimer's Disease | Phase 2 | UNKNOWN | 204 |
| [NCT01618162](https://clinicaltrials.gov/study/NCT01618162) | The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 435 |
| [NCT02501850](https://clinicaltrials.gov/study/NCT02501850) | The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) | Diabetes Mellitus Type 2 | Phase 4 | UNKNOWN | 40 |
| [NCT05111912](https://clinicaltrials.gov/study/NCT05111912) | Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity | Obesity | Phase 2 | COMPLETED | 206 |
| [NCT02505334](https://clinicaltrials.gov/study/NCT02505334) | A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 635 |
| [NCT02743598](https://clinicaltrials.gov/study/NCT02743598) | Liraglutide for HIV-associated Neurocognitive Disorder | HIV Infection, Diabetes Mellitus Type 2 | Phase 4 | TERMINATED | 4 |
| [NCT02147925](https://clinicaltrials.gov/study/NCT02147925) | Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects | Non-alcoholic Fatty Liver Disease | Phase 4 | COMPLETED | 75 |
| [NCT01541215](https://clinicaltrials.gov/study/NCT01541215) | Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 135 |
| [NCT02098395](https://clinicaltrials.gov/study/NCT02098395) | The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes | Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | COMPLETED | 835 |
| [NCT01511198](https://clinicaltrials.gov/study/NCT01511198) | Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 223 |
| [NCT02089256](https://clinicaltrials.gov/study/NCT02089256) | Effect of Repeated Administration of Liraglutide on Insulinogenic Indices | Healthy | Phase 4 | COMPLETED | 10 |
| [NCT02423824](https://clinicaltrials.gov/study/NCT02423824) | Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists | Bipolar Disorder, Major Depressive Disorder | Phase 3 | COMPLETED | 21 |
| [NCT01847313](https://clinicaltrials.gov/study/NCT01847313) | The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | Diabetic Kidney Disease | Phase 3 | COMPLETED | 20 |
| [NCT02930265](https://clinicaltrials.gov/study/NCT02930265) | Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy | Ischemic Cardiomyopathy | Not phased | UNKNOWN | 400 |
| [NCT01511159](https://clinicaltrials.gov/study/NCT01511159) | Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 32 |
| [NCT01789086](https://clinicaltrials.gov/study/NCT01789086) | A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 21 |
| [NCT00331851](https://clinicaltrials.gov/study/NCT00331851) | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 584 |
| [NCT01676116](https://clinicaltrials.gov/study/NCT01676116) | The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 438 |
| [NCT02036372](https://clinicaltrials.gov/study/NCT02036372) | Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus | Diabetes Mellitus Type II | Not phased | COMPLETED | 150 |
| [NCT02607306](https://clinicaltrials.gov/study/NCT02607306) | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 819 |
| [NCT01473953](https://clinicaltrials.gov/study/NCT01473953) | Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 31 |
| [NCT01784965](https://clinicaltrials.gov/study/NCT01784965) | Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD. | Pre-diabetes, Older Adults | Phase 3 | COMPLETED | 69 |
| [NCT02483299](https://clinicaltrials.gov/study/NCT02483299) | Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome | PCOS, Obesity | Phase 4 | COMPLETED | 40 |
| [NCT01507337](https://clinicaltrials.gov/study/NCT01507337) | Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers | Diabetes, Healthy | Phase 1 | COMPLETED | 32 |
| [NCT07225816](https://clinicaltrials.gov/study/NCT07225816) | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | Obesity | Phase 1 | RECRUITING | 71 |
| [NCT02928614](https://clinicaltrials.gov/study/NCT02928614) | Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance | Osteoarthritis, Obesity | Phase 4 | COMPLETED | 150 |
| [NCT03421119](https://clinicaltrials.gov/study/NCT03421119) | Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | UNKNOWN | 300 |
| [NCT06361238](https://clinicaltrials.gov/study/NCT06361238) | Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery | Delirium, Postoperative | Phase 3 | RECRUITING | 260 |
| [NCT02944500](https://clinicaltrials.gov/study/NCT02944500) | Saxenda: Underlying Mechanisms and Clinical Outcomes | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 28 |
| [NCT01505673](https://clinicaltrials.gov/study/NCT01505673) | Adding Liraglutide to High Dose Insulin: Breaking the Cycle | Type 2 Diabetes Mellitus, Obesity | Phase 4 | COMPLETED | 71 |
| [NCT00422058](https://clinicaltrials.gov/study/NCT00422058) | The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Metabolism and Nutrition Disorder, Obesity | Phase 2 | COMPLETED | 564 |
| [NCT01733758](https://clinicaltrials.gov/study/NCT01733758) | A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 494 |
| [NCT01753362](https://clinicaltrials.gov/study/NCT01753362) | Liraglutide In Overweight Patients With Type 1 Diabetes | Type 1 Diabetes | Phase 3 | COMPLETED | 84 |
| [NCT02408705](https://clinicaltrials.gov/study/NCT02408705) | Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects | Type 1 Diabetes Mellitus | Phase 2 | COMPLETED | 14 |
| [NCT03115099](https://clinicaltrials.gov/study/NCT03115099) | A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 80 |
| [NCT02655770](https://clinicaltrials.gov/study/NCT02655770) | Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients | Diabetes Mellitus Type 2, Diastolic Dysfunction | Phase 4 | COMPLETED | 40 |
| [NCT04763564](https://clinicaltrials.gov/study/NCT04763564) | Efficacy of Liraglutide Therapy in Patients With IPAA | Pouchitis, Irritable Pouch Syndrome | Phase 2 | TERMINATED | 8 |
| [NCT02016846](https://clinicaltrials.gov/study/NCT02016846) | Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes | Glucocorticoid Induced Hyperglycemia | Phase 3 | UNKNOWN | 36 |
| [NCT01572740](https://clinicaltrials.gov/study/NCT01572740) | Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 257 |
| [NCT04881110](https://clinicaltrials.gov/study/NCT04881110) | Liraglutide and Peripheral Artery Disease | Type 2 Diabetes, Peripheral Arterial Disease | Phase 4 | COMPLETED | 60 |
| [NCT01575301](https://clinicaltrials.gov/study/NCT01575301) | DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists | Diabetes | Not phased | COMPLETED | 411 |
| [NCT01542242](https://clinicaltrials.gov/study/NCT01542242) | Liraglutide Use in Prader-Willi Syndrome | Diabetes Mellitus Type 2, Prader Willi Syndrome | Phase 4 | TERMINATED | 1 |
| [NCT01931982](https://clinicaltrials.gov/study/NCT01931982) | Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes. | Type 2 Diabetes, Microvascular Dysfunction | Phase 4 | COMPLETED | 20 |
| [NCT01511172](https://clinicaltrials.gov/study/NCT01511172) | Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 145 |
| [NCT02420262](https://clinicaltrials.gov/study/NCT02420262) | A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 506 |
| [NCT03101930](https://clinicaltrials.gov/study/NCT03101930) | Cardiovascular Effects of GLP-1 Receptor Activation | Obesity, PreDiabetes | Phase 4 | COMPLETED | 329 |
| [NCT01937598](https://clinicaltrials.gov/study/NCT01937598) | Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D | Type 2 Diabetes | Phase 3 | COMPLETED | 16 |
| [NCT01599338](https://clinicaltrials.gov/study/NCT01599338) | Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients | Type 2 Diabetes Mellitus, Overweight | Not phased | COMPLETED | 30 |
| [NCT00978393](https://clinicaltrials.gov/study/NCT00978393) | A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 49 |
| [NCT02014740](https://clinicaltrials.gov/study/NCT02014740) | Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes | Type 2 Diabetes, Overweight | Phase 4 | COMPLETED | 100 |
| [NCT02235961](https://clinicaltrials.gov/study/NCT02235961) | Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects | Metabolism and Nutrition Disorder, Obesity | Phase 1 | COMPLETED | 163 |
| [NCT01677104](https://clinicaltrials.gov/study/NCT01677104) | The Microvascular Function of GLP-1 and Its Analogues | Type 2 Diabetes, Obesity | Not phased | COMPLETED | 63 |
| [NCT04829903](https://clinicaltrials.gov/study/NCT04829903) | Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin | Type 2 Diabetes Treated With Insulin, Obesity | Not phased | COMPLETED | 116 |
| [NCT03737240](https://clinicaltrials.gov/study/NCT03737240) | IDegLira HIGH Trial | Diabetes Mellitus | Phase 3 | COMPLETED | 145 |
| [NCT01399645](https://clinicaltrials.gov/study/NCT01399645) | Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes | Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 35 |
| [NCT02140983](https://clinicaltrials.gov/study/NCT02140983) | Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes | Insulin Resistance, Dementia | Phase 1 | COMPLETED | 41 |
| [NCT01394341](https://clinicaltrials.gov/study/NCT01394341) | Liraglutide Treatment to Patients With Severe Renal Insufficiency | Type 2 Diabetes Mellitus, End-stage Renal Disease | Phase 4 | COMPLETED | 40 |
| [NCT03986008](https://clinicaltrials.gov/study/NCT03986008) | Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients | Obesity | Phase 3 | UNKNOWN | 60 |
| [NCT01516476](https://clinicaltrials.gov/study/NCT01516476) | Study of RO6807952 in Patients With Diabetes Mellitus Type 2 | Diabetes Mellitus Type 2 | Phase 2 | TERMINATED | 2 |
| [NCT02461589](https://clinicaltrials.gov/study/NCT02461589) | Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 706 |
| [NCT03182426](https://clinicaltrials.gov/study/NCT03182426) | Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) | Diabetes Mellitus, Type 1 | Phase 2 | COMPLETED | 22 |
| [NCT00318422](https://clinicaltrials.gov/study/NCT00318422) | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1041 |
| [NCT02492763](https://clinicaltrials.gov/study/NCT02492763) | A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) | Type II Diabetes Mellitus | Phase 2 | TERMINATED | 176 |
| [NCT03856632](https://clinicaltrials.gov/study/NCT03856632) | Liraglutide Effect in Atrial Fibrillation | Atrial Fibrillation | Phase 4 | ACTIVE_NOT_RECRUITING | 60 |
| [NCT01507311](https://clinicaltrials.gov/study/NCT01507311) | Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 11 |
| [NCT03151005](https://clinicaltrials.gov/study/NCT03151005) | The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Polycystic Ovary Syndrome (PCOS), Overweight | Phase 4 | COMPLETED | 70 |
| [NCT02911818](https://clinicaltrials.gov/study/NCT02911818) | Lifestyle Modification and Liraglutide | Obesity | Phase 4 | COMPLETED | 150 |
| [NCT02315001](https://clinicaltrials.gov/study/NCT02315001) | Liraglutide to Improve corONary Haemodynamics During Exercise streSS | Ischaemic Heart Disease, Coronary Heart Disease | Phase 2 | COMPLETED | 26 |
| [NCT05041673](https://clinicaltrials.gov/study/NCT05041673) | Anti-diabetic Drugs and Fatty Liver Management | Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2 | Not phased | UNKNOWN | 120 |
| [NCT02113332](https://clinicaltrials.gov/study/NCT02113332) | Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 124 |
| [NCT05029076](https://clinicaltrials.gov/study/NCT05029076) | Human Bioequivalence Test of Liraglutide Injection | Type 2 Diabetes | Phase 1 | COMPLETED | 28 |
| [NCT01469351](https://clinicaltrials.gov/study/NCT01469351) | Identifying Potential Effects of Liraglutide on Degenerative Changes | Alzheimers Disease | Not phased | COMPLETED | 34 |
| [NCT02527993](https://clinicaltrials.gov/study/NCT02527993) | Treatment of Hypoglycemia Following Gastric Bypass Surgery | Hypoglycemia, Obesity | Phase 4 | COMPLETED | 11 |
| [NCT02059564](https://clinicaltrials.gov/study/NCT02059564) | A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Diabetes Mellitus | Phase 1 | UNKNOWN | 44 |
| [NCT01597531](https://clinicaltrials.gov/study/NCT01597531) | Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding | Type 2 Diabetes, Gastric Banding | Phase 4 | TERMINATED | 1 |
| [NCT02879409](https://clinicaltrials.gov/study/NCT02879409) | HbA1c Variability in Type II Diabetes | Diabetes Mellitus Type 2 | Not phased | ACTIVE_NOT_RECRUITING | 150 |
| [NCT00614120](https://clinicaltrials.gov/study/NCT00614120) | Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 929 |
| [NCT01612468](https://clinicaltrials.gov/study/NCT01612468) | Liraglutide in Type 1 Diabetes | Diabetes Mellitus, Type 1, Overweight | Phase 4 | COMPLETED | 100 |
| [NCT02660047](https://clinicaltrials.gov/study/NCT02660047) | Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent | Diabetes Mellitus Type 2, Metabolic Syndrome | Phase 4 | COMPLETED | 51 |
| [NCT01508949](https://clinicaltrials.gov/study/NCT01508949) | Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 35 |
| [NCT04657939](https://clinicaltrials.gov/study/NCT04657939) | Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 57 |
| [NCT01899430](https://clinicaltrials.gov/study/NCT01899430) | Polycystic Ovary Syndrome and Liraglutide | PCOS, Obesity | Phase 4 | COMPLETED | 32 |

## Common questions

**How many human trials does Liraglutide have?**
419, each listed above with a link to its original record.

**Is Liraglutide FDA approved?**
Yes — FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/liraglutide*